Health

Hospitals Could Make More Drugs In-House Under Trump Proposal

A lab technician uses a multichannel pipette dropper during the antigen quantification process of the coronavirus vaccine research at the Valneva SA laboratories in Vienna, Austria, on Thursday, Aug. 6, 2020. The U.K. has signed agreements to buy 90 million doses of vaccines in development by drugmakers including Pfizer Inc., BioNTech SE and Valneva SE, joining countries around the world racing to secure supplies of protection against Covid-19.Photographer: Akos Stiller/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Jessica Nix

May 15, 2025 at 8:55 PM UTC

This article is for subscribers only.

The Trump administration wants to bring the production of more drugs, including medicines like antibiotics that may be in short supply, closer to the patient — including inside the hospital.

The partnership between some of the nation’s top health agencies and a handful of companies, including the Mark Cuban Cost Plus Drug Company, is intended to use artificial intelligence and other tools to make eight drugs in the places where people actually get medical care. The treatments include generic drugs such as levetiracetam, which treats epilepsy, the local anesthetic lidocaine, the chemotherapy carboplatin, albuterol sulfate for asthma and the antibiotic linezolid.